Diagnosing hyperglycemia (GDM) in pregnancy: closing the door after the horse has
bolted?

Short title: GDM is not gestational

Chittaranjan S. Yajnik, Souvik Bandyopadhyay, Dattatray S. Bhat, Rucha S.H. Wagh, Pallavi
C. Yajnik, Rasika Ladkat, Kurus Coyaji and Caroline H.D. Fall

Affiliations

Chittaranjan S Yajnik	MD	Diabetes Unit, KEM Hospital Research Centre, Pune, India	csyajnik@gmail.com
Souvik Bandyopadhyay	PhD	Cytel, Inc., Cambridge, MA, USA	bansouvik@gmail.com
Dattatray S Bhat	MSc	Diabetes Unit, KEM Hospital Research Centre, Pune, India	dsbhat2004@yahoo.co.in
Rucha SH Wagh	MSc	Diabetes Unit, KEM Hospital Research Centre, Pune, India Symbiosis Institute of Biological Sciences, Symbiosis International (Deemed) University, Pune, MH, India	ruchaw3@gmail.com
Pallavi C Yajnik	MCom	Diabetes Unit, KEM Hospital Research Centre, Pune, India	pallaviyajnik@yahoo.com
Rasika Ladkat,	MA	Diabetes Unit, KEM Hospital Research Centre, Pune, India	r.ladkat@kemhrcpune.org
Kurus Coyaji	MD	Diabetes Unit, KEM Hospital Research Centre, Pune, India	kcoyaji@kemhospital.org
Caroline HD Fall	DM	MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK	chdf@mrc.soton.ac.uk

8 Corresponding author
9 Professor Chittaranjan S Yajnik Director, Diabetes Unit
10 KEM Hospital Research centre Pune, India
11 csyajnik@gmail.com; +91 98228 47481
12

13 Word counts Abstract 360
14 Main text 3219
15 Figures: 5, tables: 1
16

Abstract

Introduction: A common belief is that gestational hyperglycemia ('GDM') develops during pregnancy and remits after delivery. It increases the risk of diabetes and obesity in the offspring and fuels the intergenerational epidemic of diabesity in the young. Intensive glycemic treatment in pregnancy RCTs failed to prevent this transmission because the critical pre- and peri-conceptional window for epigenetic programming was missed. Some studies have reported that women diagnosed with GDM were already hyperglycemic, obese, and insulin resistant before pregnancy. However, little is known about the life-course evolution of glycemia before the diagnosis of pregnancy hyperglycemia. The Pune Maternal Nutrition Study (PMNS) birth cohort has measured plasma glucose serially throughout childhood, puberty, young adulthood, pregnancy, and later, providing a unique opportunity to test the hypothesis that pregnancy hyperglycemia is only a window in lifetime hyperglycemia.

Methods: The PMNS birth cohort, established in 1993, included serial glucose measurements at ages 6, 12, and 18 years, as well as for females during pregnancy and post-delivery follow-up. Of 366 female cohort members, 171 became pregnant and delivered by February 2020. Given the small number of GDM (IADPSG criteria) we defined pregnancy hyperglycemia as the upper quartile (Q4) of fasting plasma glucose (FPG) and area under the curve (AUC) during an OGTT at 28 weeks gestation.

Results: At 28wks gestation these women were young (mean age 20.9y) and had a median BMI 21.7 kg/m^2 [IQR, 20.0, 23.8]; 44 women had fasting hyperglycemia (FPG >4.7 mmol/l) and 39 had AUC hyperglycemia (AUC > 8.57 x 10^2). For both groups, hyperglycemic women had higher glycemia from childhood through post-delivery compared to normoglycemic women, and higher HbA1c before pregnancy. Having an FPG above the highest quartile from childhood increased the odds of pregnancy hyperglycemia 2.22 times (95% CI 1.45, 3.38),

and post-delivery glucose intolerance 5.22 times (2.40, 11.33); for AUC, the odds were 2.88

(1.31, 6.28) and 3.50 (1.36, 8.97) respectively.

Interpretation: Pregnancy hyperglycemia reflects persistent hyperglycemia since childhood.

Diagnosing and managing hyperglycemia ('GDM') in pregnancy does not prevent exposure

of the ovum and early embryo to an abnormal metabolic milieu and will not curtail the

escalating epidemic of diabesity in the offspring. A pre-conceptional 'primordial' approach is

essential.

Keywords: Gestational hyperglycemia, GDM, life-course evolution, peri-conceptional

programming, diabesity

Research in context

Evidence before this study:

- Most clinicians and researchers believe that 'gestational' diabetes develops during pregnancy and remits after delivery

- Some studies have reported higher glucose, HbA1c, lipids, and BMI years before diagnosis of GDM but these are underplayed as 'risk factors'

- Randomised controlled trials of intensive glycemic control in pregnancy (usually initiated in the third trimester) do not prevent the long-term risk of diabetes and obesity in the offspring

- This may be partly due to genetic transmission but more likely due to pre- and peri-conceptional epigenetic programming due to maternal metabolic status

What's new in this study:

- We describe for the first time a life course trajectory of glycemia and body size in women with pregnancy hyperglycemia, in the Pune Maternal Nutrition Study, a preconceptional birth cohort initiated 30 years ago

- Women with pregnancy hyperglycemia had consistently elevated glycemia from childhood, puberty, and young adulthood through pregnancy and post-pregnancy

- This demonstrates that pregnancy hyperglycemia is only a window in the life course hyperglycemia and not a *de novo* phenomenon.

Implications of all the available evidence:

- Our findings suggest that primordial prevention of the intergenerational vicious cycle of diabetes and obesity may be achieved by management of metabolic abnormalities before pregnancy

75   • This will shift the focus from the clinic to the community, from clinical medicine to

76   public health

77   • Further research will define the role of genetic and epigenetic factors involved

Introduction

The IDF Atlas 2025 estimates that every year 23 million babies (19.7 % of all pregnancies) in the world are born in a 'hyperglycemic' pregnancy, and an overwhelming majority of these are first discovered only during pregnancy, so-called gestational diabetes (GDM) (1). The majority of GDM cases are in low-and middle-income countries (LMICs). Current standards of practice recommend diagnosing GDM at 24-28 weeks of gestation (2). In addition to adverse pregnancy outcomes involving both the mother and the baby (3), GDM increases risk of diabetes, obesity and cardiovascular disease (CVD) in the child (4-6), referred to as the 'vicious cycle of diabetes' (7). RCTs of intensive treatment of GDM have shown a reduction in the incidence of large for gestational-age (LGA) / macrosomia and associated obstetric problems but have failed to protect the offspring against childhood obesity and glucose intolerance (8-11). This could be ascribed to genetic transmission and/or to fetal epigenetic programming of these conditions (12). Pima Indian data favoured the latter over genetic factors (6)

GDM is generally viewed as a transitory phenomenon, due to the metabolic-endocrine stress of pregnancy (4). It is a general belief that it develops during pregnancy and resolves after the delivery of the child. There is increasing evidence that the metabolic abnormalities of GDM (hyperglycemia, low insulin secretion, and insulin resistance) precede pregnancy. This was reported in the pioneering serial metabolic studies before and during pregnancy by Catalano (13), in clinic- based data in California (USA) (14), in the CARDIA (USA) (15) and MUSP (Australia) cohorts (16), in the Cardiovascular Risk in Young Finns Study (17), and a population-based study in Ontario Canada (18). However, we could not find any reports in the literature of a life course trajectory of glycemic measurements in women diagnosed with pregnancy hyperglycemia.

The Pune Maternal Nutrition Study (PMNS) is a pre-conceptional birth cohort study in six

villages near Pune, India, with a 30-year follow-up since its inception in 1993 (19, 20). Data

are available on 3 successive generations (F0, F1, F2). In the female offspring (F1) born in

the PMNS, serial measurements of body size and glucose-insulin metabolism are available

from birth, through childhood, puberty and adolescence, to their first pregnancy and after

delivery. Glucose tolerance information is also available in their mothers (F0) when pregnant

with the F1 child. This provided us with a unique opportunity to construct a life course

trajectory of glycemia in F1 mothers with pregnancy hyperglycemia. We tested the

hypothesis that pregnancy hyperglycemia originates in early life, not during pregnancy. This

may help assess the appropriateness of the current clinical practice of diagnosing and treating

GDM in pregnancy, and its implications for intergenerational transfer of risk of diabesity and

the potential window for its primordial prevention.

Methods

The PMNS was established in 1993 in six villages near Pune, India to study determinants of fetal growth and to study life-course evolution of cardio-metabolic risk factors (Figure 1) (19).

F0 generation

Briefly, married, non-pregnant women (N=2,466) were followed up regularly for menstrual history and body size measurements (ESM fig. 1). They were recruited into the main study when a singleton pregnancy of <21 weeks' gestation was confirmed by ultrasound. Maternal medical, nutritional, and biochemical information was obtained at 18- and 28-weeks' gestation, including a 75gm fasting OGTT at 28-weeks. Deliveries happened at home or local health centres.

Lifecourse measurements of F1 generation from birth to 18-years

Anthropometric measurements were made using standardized protocols at birth and during subsequent follow-ups (ESM table 1) (20). At age 6 years, a 1.75g/kg oral glucose tolerance test (OGTT), and at 18 years a 75g OGTT were performed (fasting, 30- and 120-min venous blood samples). At 12 years, only a fasting blood sample was collected. Plasma glucose was measured by GOD-POD method on an automated system, within and between batch CV was <3% (ESM table 2). HbA1c was measured on Bio-Rad D10 system (Bio-Rad labs, Hercules, CA, USA) between 15- and 17-years of age.

Pregnancy

Marriage and pregnancy were recorded by the field staff. At 28 weeks' gestation, a fasting OGTT (75g anhydrous glucose, fasting, 60- and 120-mins venous samples) was performed.

GDM was diagnosed by the IADPSG criteria (21) and appropriately treated. Neonatal

anthropometry (F2) was performed using standardized methods.

Post-delivery follow-up

At ~24 years of age, F1 women underwent a 75gm OGTT, results were classified by ADA

criteria (2). This activity was suspended due to the COVID pandemic (Mar 2020) and

resumed in 2022. We used data collected until January 2024 for this analysis.

Definitions

In F0 mothers, GDM was diagnosed by WHO 1985 criteria (75gm fasting OGTT) (22). In

the F1 generation, GDM was diagnosed by IADPSG criteria (21). Given the small number of

GDM cases (n=20/158, 12.6%), to increase statistical power for this paper, we defined

'fasting hyperglycemia' in F1 mothers as those in the highest quartile of fasting plasma

glucose concentrations (FPG) (Q4 $\geq$ 4.7 mmol/l) and considered Q1+Q2+Q3 as

'normoglycemia'. Similarly, we also calculated Q4 for the area under the curve (AUC) for

OGTT glucose concentrations by the trapezoidal rule (Q4 $\geq$ 8.57 x 10^2). We calculated

similar Q4s for FPG (6-, 12-, and 18-years) and OGTT AUC (6- and 18-years).

Statistical analysis

Our main analysis is to compare the life-course evolution of glycemia and body size

measurements in women (F1) with and without pregnancy hyperglycemia at 28-wks gestation

(fasting and OGTT AUC). Variables with skewed distributions were normalized by log

transformation. All variables were converted to z-scores, and differences between

normoglycemic and hyperglycemic participants were expressed in z-score units with 95% CIs

and tested using *t*-test statistics. The life-course evolution of glycemic and size measurements

is shown as serial line plots (mean $\pm$ SEM) for those with and without pregnancy

hyperglycemia.

We calculated odds ratios to estimate the risk of having pregnancy hyperglycemia (FPG and

AUC) for Q4 of FPG at 6, 12, and 18 years, and Q4 of AUC at 6 and 18 years. Similarly, we

estimated the risk of being glucose intolerant (prediabetes+diabetes) at 24 years for Q4 of

FPG at 6, 12 and18-years and 28 weeks gestation, and for Q4 of AUC at 6 and 18 years and

28wks gestation. The odds ratios are represented using forest plots.

All statistical analyses were performed using SPSS v26 and R 4.0.5 software.

Ethics

The study was approved by village leaders and the KEM Hospital Research Centre Ethics

Committee, Pune, India at all timepoints. Participants >18 years of age signed an informed

consent. Children <18 years of age provided assent along with parental consent.

Data sharing statement: Data are available for additional analyses by applying to the

corresponding author with a 200-word plan of analysis. Data sharing is subject to KEMHRC

Ethics Committee approval and the Government of India's Health Ministry Screening

Committee (HMSC) permission.

Results

Cohort Description (figure 1, ESM figure S1)

F0 mothers (1993-96, n= 762) were 21.2 years old, 1.52 m tall, with a median BMI of 20.2 kg/m^2 at 28wks gestation, and a third were primiparous. A 75g fasting OGTT was available on 598, median FPG was 3.9 mmol/l and 2h value was 4.3 mmol/l; only 3 were diagnosed GDM by WHO 1985 criteria. Three hundred and sixty-six live singleton daughters (birthweight 2.55 kg) and 396 sons (2.70 kg) were born in the study (F1, 1994-96). By February 2020, 195 F1 daughters had married, become pregnant and delivered. Our analysis includes 171 of these with fasting glucose and 158 with 75g OGTT data at 28 weeks gestation. They were 20.9 years old, 1.57 m tall, with a median BMI of 21.7 kg/m^2, all were primiparous. Eighty-four live singleton daughters (2.78 kg) and eighty-five sons (2.75 kg) were born (F2). One hundred and thirty-six F1 daughters also attended a post-delivery follow-up (2019-24) including a 75g OGTT at an average age of 24.3 years, and a median BMI 21.3 kg/m^2.

Compared to those not included in this analysis, the included F1 daughters had similar birthweight, and BMI and FPG at 6, 12, and 18y (ESM table 3).

F1 daughters: glycemia and body size

At 28wks gestation, median FPG concentration was 4.4 mmol/l and 120 mins 6.3 mmol/l. Forty-four women fulfilled our definition of fasting hyperglycemia (Q4), and 39 using the AUC definition (Q4). Twenty women (12.6% of 158) were diagnosed GDM based on IADPSG criteria. At 24 years of age, 21 (15%) had glucose intolerance by ADA criteria (12 IFG, 5 IGT, 4 IFG+IGT).

Glycemic and body size trajectories of F1 women with and without pregnancy hyperglycemia (Table 1, Figure 2)

At 28wks gestation, women with fasting pregnancy hyperglycemia were 20.3 years old, and

were heavier (23.3 vs 21.2 kg/m2) compared to the normoglycemic women; height and

gestational weight gain (8.9 vs 8.9 kg) were similar (Table 1). There was no difference in

their mother's glucose levels during pregnancy (F0) (Table 1). Women with pregnancy

hyperglycemia had consistently higher levels of FPG and OGTT AUC starting from

childhood (6 years), through puberty (12 years) and young adulthood (18 years) (Table 1,

Figure 2). The prevalence of IFG was higher at 12 years (4.5% vs 0.8%) and 18 years (15%

vs 4.9%), and they also had higher HbA1c concentrations at 15-17 years of age (mean diff

+0.27 SD, p<0.07). Post-delivery, women with fasting pregnancy hyperglycemia continued to

have higher glycemia, and a substantially higher proportion (38% vs 9%) had glucose

intolerance (prediabetes) compared to those with pregnancy normoglycemia.

Similarly, women with pregnancy OGTT AUC hyperglycemia had higher OGTT AUC at 6-

years and 18-years, and higher HbA1c at 15-17-years. They continued to have higher

glycemia post-delivery (table 1, figure 2).

Prediction of pregnancy and post-pregnancy hyperglycemia by early life hyperglycemia

(Figure 3 & 4)

Figure 3 shows that the prevalence of pregnancy hyperglycemia (both fasting and OGTT-

AUC) progressively increased with increasing glycemia in early life; the forest plot shows

that the cumulative risk was 2.22 [1.45-3.38] times higher for the Q4 of FPG and 2.88 [1.32-

6.28] times for the Q4 of OGTT AUC. Figure 4 shows that the prevalence of post-pregnancy

glucose intolerance progressively increased with increasing glycemia in pregnancy; the forest

plot shows that the cumulative risk was 5.22 [2.40-11.33] time higher for the Q4 of FPG and

3.50 [1.36-8.97] times higher for the Q4 of OGTT AUC. All these risks remained similar and

significant after adjusting for BMI or waist circumference.

Trajectories of body size and growth (fig 2 and 5)

Our serial measurements from birth allowed us to study the life-course evolution of body size

and growth in women with and without pregnancy hyperglycemia. Birth size was similar in

those with and without fasting pregnancy hyperglycemia, however hyperglycemic women

had experienced an early catch-up in height (at 2 and 6 years) and had higher weight, BMI

and waist circumference from childhood through puberty, young adulthood, and post-

pregnancy. It is noteworthy that, up to 18-years, the major issue in this population was

'undernutrition' (low BMI).

Women with pregnancy OGTT AUC hyperglycemia were lighter, shorter, and had smaller

abdominal circumference at birth but their size after birth was no different than those with

normoglycemia.

Discussion

We present unique data to show that gestational hyperglycemia is only a window in the life-

long hyperglycemic trajectory of that woman. We show tracking of fasting and post-glucose

load glycemia (OGTT AUC) in female participants born in the PMNS birth cohort from their

early childhood into puberty, early adulthood, pregnancy, and post-delivery. To the best of our

knowledge, this is the first demonstration of such life course tracking. Our previous report on

larger number of PMNS participants (male+female) showed that hyperglycemia at 18 years

of age was significantly correlated also with higher maternal glycemia, which suggests that

the tracking extends intergenerationally (20). These findings challenge the popular belief that

'gestational' hyperglycemia has a *de novo* onset during pregnancy and resolves after delivery.

Thus, our findings have important implications for the definition, diagnosis, treatment,

follow-up, and fetal programming effects of the condition called 'GDM'.

The majority of reports in the literature concentrate on the increased risk of post-pregnancy

diabetes in GDM women. Only a few studies have reported glucose metabolism in the pre-

pregnancy period, but none in a life course model. Catalano's classic studies of 38 women

before and during early and late pregnancy showed that women subsequently diagnosed with

GDM had higher glycemia and lower insulin sensitivity before pregnancy and maintained

their differences from non-GDM women in early and late pregnancy (13). A Kaiser

Permanente study in California showed that women diagnosed with GDM had higher BMI,

higher glycemia, and dyslipidemia years before pregnancy, compared to women without

GDM (14). Similarly, women diagnosed with GDM in the CARDIA cohort (15), MUSP

cohort of aboriginal women in Australia (16), and the Cardiovascular Risk in Young Finns

Study (17) had higher glycemia (glucose, HbA1c) before pregnancy. A recent demonstration

of higher HbA1c values in early pregnancy in those subsequently diagnosed with GDM

strongly suggests higher glycemia before pregnancy (23). Data from population-based

administrative databases in Canada showed that women diagnosed with GDM during

pregnancy already had elevated levels of fasting and random glucose, HbA1c, and

dyslipidemia a few years before pregnancy (18,24). None of these studies have reported early

childhood and intergenerational measurements. Outside pregnancy, many studies including

Bogalusa Heart Study (25), the Early Bird study (26), i3C (27), and three Pune cohorts (20)

have demonstrated tracking of glycemia from early life into young adulthood.

Ideas about the adverse clinical effects of gestational hyperglycemia have evolved since the

1960's. The original concept was based on an increased post-partum risk of diabetes in the

mother (28). Adverse pregnancy outcomes (3) and an increased risk of diabesity in the

offspring were added later (29). Adverse pregnancy outcomes are mostly related to fetal

overnutrition and consequent overgrowth (due to maternal glucose, lipids etc) and maternal

co-morbidities (higher age, obesity, high blood pressure etc). The long-term risk of offspring

diabesity is ascribed to fetal epigenetic programming ('teratogenesis') by the maternal

metabolic milieu, in addition to the role of genetics (12). We now understand that the

strongest window for epigenetic programming is pre- and periconceptional (preimplantation)

(30, 31). Our data suggest that the ova and the early embryo of a woman subsequently

diagnosed with gestational hyperglycemia will have been exposed to the yet undiagnosed

hyperglycemia (and other metabolic problems) from an early age which could cause

epigenetic modifications during gametogenesis, gamete maturation and early embryonic

development and increase the risk of future diabesity. Thus, our findings have important

implications for the timing of diagnosis and treatment of hyperglycemia to avoid

programming of diabetes in the offspring and to curtail the escalating epidemic of diabetes in

the young. The current practice of diagnosing and treating GDM in the third trimester

partially reduces overgrowth of the baby but not the long-term risk of diabetes and obesity

(10,11). Pre-gestational hyperglycemia in mice epigenetically reduced the expression of the

TET3 gene (involved in DNA demethylation) and suppressed the expression of the *GCK* and

other genes involved in insulin secretion in developing pancreatic islets, to increase the risk

of diabetes in the offspring (32). Similar changes were observed in blastocysts of

hyperglycemic women. The pancreatic islets from hyperglycemic donors showed epigenetic

changes (DNA methylation) in the B-cells, which predisposed the recipient to future diabetes

(33). Our preliminary investigation of circulating miRNAs in serial samples from women in

the PMNS demonstrated a differential signature from early childhood in those with

prediabetes at 18-years of age (34). These studies strongly support the thesis that the

preceding lifelong dysglycemia in women diagnosed with 'GDM' will have already altered

the 'epigenetic profile' in the ova and the embryo before diagnosis of GDM and increase the

risk of diabetes in the offspring.

The main strength of our study is the serial metabolic and anthropometric data from

childhood to pregnancy and the post-pregnancy period, spanning 30 years, collected using

standardised methods and with high rates of follow-up. This allowed us to construct a

trajectory that was not possible before. Our results show that the 'glucostat' is set very early

in life for both fasting and post-glucose (OGTT) glycemia.

Limitations are that our study, being intense, was relatively small, and despite a moderately

high prevalence of GDM (12.6%) there were only 20 cases. To increase statistical power, we

defined hyperglycemia during pregnancy in our women using the upper quartiles of fasting

glucose or the OGTT AUC. This could appear as a major limitation, but for the following

reasons: 1) Very importantly, the HAPO study showed clearly that there are continuous and

graded associations without any thresholds, between maternal glucose concentrations

(fasting, 1h and 2h during an OGTT) and neonatal outcomes (macrosomia, hyperinsulinemia,

hypoglycemia, and Caesarean section rates). Consensual and arbitrary statistical cut-points

were defined in the absence of a relevant glycemic threshold for adverse outcomes which

became the IADPSG criteria (21). Thus, both the exposures and outcomes in the HAPO study

were centile-based, 2) Even after HAPO study and the IADPSG criteria, there is considerable

disagreement about the criteria to diagnose GDM across the world. Though both WHO and

ADA have accepted the IADPSG criteria, many countries have not (UK, Australasia,

Denmark, Norway, and many centres in the USA and India), 3) Moreover, there was no

representation in the HAPO study from the undernourished populations of the world. India,

which is estimated to contribute a substantial number of GDM cases in the world (1) was not

represented. Indian national average birth weight is 2.8 kg and intrauterine growth restriction

is common, raising doubts about the applicability of the fetal overgrowth-based criteria from

the high-income countries. The generalizability of our findings to other populations will need

to be confirmed; however, available data (discussed above) indicates that the biology of life-

course tracking is universal.

Our findings have the potential to change clinical thinking and public health practice. The

preconceptional period provides an important opportunity to curtail developmental

programming of diabetes, obesity and other non-communicable diseases (30, 31). This shifts

the attention from the clinic to the community, from clinical practice to public health.

Controlling lifestyle factors which promote diabesity during childhood and adolescence

qualifies as 'primordial' prevention for the next generation. This will need cooperation

between medical professionals, parents, schools, and governmental and non-governmental

agencies to promote health literacy/education. This invites considerable efforts from the

health system and expects a change in human behaviour. This is different from the currently

popular practice of 'primary' prevention by targeting adults with prediabetes and obesity.

Geoffrey Rose highlighted the larger benefits of intervening to favourably shift the curve

rather than concentrating on the tail-end of the distribution (35). Fortification of flour with

folic acid to prevent neural tube defects, and strict control of pre-gestational diabetes to

prevent congenital anomalies are prime examples of successful primordial prevention.

In summary, we report novel data showing lifecourse tracking of glycemia from childhood in

women diagnosed with gestational hyperglycemia. It is clear that gestational glycemia is only

a window in the life-course evolution of metabolism. 'GDM' is not a *de novo* disorder of

pregnancy as highlighted in a review many years ago (36). John Jarrett aptly commented that

'gestational diabetes is simply a case of impaired glucose tolerance temporally associated

with pregnancy' (37). Maureen Harris also commented similarly (38). Our findings have

implications for prevention of pre- and periconceptional epigenetic programming of diabetes

and obesity which goes unattended in the current practice of diagnosing GDM in pregnancy

(even at the booking visit) (39). A life-course 'primordial' approach to improve metabolic

health of females from early life will be necessary to curtail the 'vicious intergenerational

cycle' of diabesity in their offspring.

References

1. International Diabetes Federation (2025) IDF Diabetes Atlas, 11th edn. Brussels,
Belgium: International Diabetes Federation. ISBN: 978-2-930229-96-6. Available at:
https://diabetesatlas.org

2. American Diabetes Association (2024) Diagnosis and classification of diabetes:
Standards of care in diabetes—2024. Diabetes Care 47(Suppl 1):S20–S42.
https://doi.org/10.2337/dc24-S002

3. National Diabetes Data Group (1979) Classification and diagnosis of diabetes
mellitus and other categories of glucose intolerance. Diabetes 28(12):1039–1057

4. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P (2019)
Gestational diabetes mellitus. Nat Rev Dis Primers 5(1):47

5. Pettitt DJ, Baird HR, Aleck KA, Bennett PH, Knowler WC (1983) Excessive obesity
in offspring of Pima Indian women with diabetes during pregnancy. N Engl J Med
308(5):242–245

6. Dabelea D, Pettitt DJ (2001) Intrauterine diabetic environment confers risks for type
2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J
Pediatr Endocrinol Metab 14(8):1085–1092

7. Pettitt DJ, Jovanovic L (2007) The vicious cycle of diabetes and pregnancy. Curr
Diab Rep 7(4):295–297

8. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS (2005)
Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J
Med 352(24):2477–2486

9. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al (2009) A
multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J
Med 361(14):1339–1348

10. Gillman MW, Oakey H, Baghurst PA, Volkmer RE, Robinson JS, Crowther CA (2010) Effect of treatment of gestational diabetes mellitus on obesity in the next generation. Diabetes Care 33(5):964–968

11. Landon MB, Rice MM, Varner MW, Casey BM, Reddy UM, Wapner RJ, et al (2015) Mild gestational diabetes mellitus and long-term child health. Diabetes Care 38(3):445–452. https://doi.org/10.2337/dc14-2159

12. Dieguez AC, Kuang A, Josefson JL, Scholtens DM, Lowe WL Jr, Hayes MG, et al (2025) In utero exposure to maternal hyperglycaemia and offspring type 2 diabetes genetic risk score are independently associated with risk of impaired glucose tolerance in youth. Diabetes Care. https://doi.org/10.2337/dc24-2891

13. Catalano PM, Huston L, Amini SB, Kalhan SC (1999) Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 180(4):903–916

14. Han ES, Krauss RM, Xu F, Sridhar SB, Ferrara A, Quesenberry CP, et al (2016) Prepregnancy adverse lipid profile and subsequent risk of gestational diabetes. J Clin Endocrinol Metab 101(7):2721–2727

15. Gunderson EP, Quesenberry CP Jr, Jacobs DR Jr, Feng J, Lewis CE, Sidney S (2010) Longitudinal study of pre-pregnancy cardiometabolic risk factors and subsequent risk of gestational diabetes mellitus: the CARDIA study. Am J Epidemiol 172(10):1131–1143

16. Alwash S, McIntyre D, Mamun A (2023) The pre-pregnancy fasting blood glucose, glycated hemoglobin and lipid profiles as blood biomarkers for gestational diabetes mellitus: evidence from a multigenerational cohort study. J Matern Fetal Neonatal Med 36(1):2195524

17. Harville EW, Viikari JS, Raitakari OT (2011) Preconception cardiovascular risk

factors and pregnancy outcome. Epidemiology 22:724–730

18. Retnakaran R, Shah BR (2020) Divergent trajectories of cardiovascular risk factors in

the years before pregnancy in women with and without gestational diabetes mellitus:

a population-based study. Diabetes Care 43(10):2500–2508

19. Rao S, Yajnik CS, Kanade A, Fall CH, Margetts BM, Jackson AA, et al (2001) Intake

of micronutrient-rich foods in rural Indian mothers is associated with the size of their

babies at birth: Pune Maternal Nutrition Study. J Nutr 131(4):1217–1224

20. Yajnik CS, Bandopadhyay S, Bhalerao A, Bhat DS, Phatak SB, Wagh RH, et al

(2021) Poor in utero growth, and reduced β-cell compensation and high fasting

glucose from childhood, are harbingers of glucose intolerance in young Indians.

Diabetes Care 44(12):2747–2757

21. International Association of Diabetes and Pregnancy Study Groups Consensus Panel,

Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al (2010)

International association of diabetes and pregnancy study groups recommendations

on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care

33(3):676–682. https://doi.org/10.2337/dc09-1848

22. WHO Study Group on Diabetes Mellitus (1985) Diabetes mellitus: report of a WHO

study group. WHO Technical Report Series, No. 727, pp 9–17

23. Saravanan P, Deepa M, Ahmed Z, Ram U, Surapaneni T, Kallur SD, et al (2024)

Early pregnancy HbA1c as the first screening test for gestational diabetes: results

from three prospective cohorts. Lancet Diabetes Endocrinol 12(8):535–544

24. Retnakaran R, Shah BR (2021) Impact of pregnancy on the trajectories of

cardiovascular risk factors in women with and without gestational diabetes. Diabetes

Obes Metab 23(10):2364–2373

421 25. Nguyen QM, Srinivasan SR, Xu JH, Chen W, Kieltyka L, Berenson GS (2010)

422  Utility of childhood glucose homeostasis variables in predicting adult diabetes and

423  related cardiometabolic risk factors: the Bogalusa Heart Study. Diabetes Care

424  33:670–675

425 26. Jeffery AN, Metcalf BS, Hosking J, Streeter AJ, Voss LD, Wilkin TJ (2012) Age

426  before stage: insulin resistance rises before the onset of puberty: a 9-year longitudinal

427  study (EarlyBird 26). Diabetes Care 35:536–541

428 27. Hu T, Jacobs DR Jr, Sinaiko AR, et al (2020) Childhood BMI and fasting glucose and

429  insulin predict adult type 2 diabetes: the International Childhood Cardiovascular

430  Cohort (i3C) Consortium. Diabetes Care 43:2821–2829

431 28. O'Sullivan JB, Mahan CM (1964) Criteria for the oral glucose tolerance test in

432  pregnancy. Diabetes 13:278–285

433 29. Freinkel N (1980) Banting Lecture 1980: Of pregnancy and progeny. Diabetes

434  29(12):1023–1035

435 30. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et

436  al (2018) Origins of lifetime health around the time of conception: causes and

437  consequences. Lancet 391(10132):1842–1852

438 31. Stephenson J, Heslehurst N, Hall J, Schoenaker DA, Hutchinson J, Cade JE, et al

439  (2018) Before the beginning: nutrition and lifestyle in the preconception period and

440  its importance for future health. Lancet 391(10132):1830–1841

441 32. Chen B, Du YR, Zhu H, Sun ML, Wang C, Cheng Y, et al (2022) Maternal

442  inheritance of glucose intolerance via oocyte TET3 insufficiency. Nature

443  605(7911):761–766

33. Rönn T, Perfilyev A, Oskolkov N, Ling C (2024) Predicting type 2 diabetes via machine learning integration of multiple omics from human pancreatic islets. Sci Rep 14(1):14637

34. Joglekar MV, Kunte PS, Wong WKM, Bhat DS, Satoor SN, Patil RR, Karandikar MS, Fall CHD, Yajnik CS, Hardikar AA (2022) Circulating microRNAs from early childhood and adolescence are associated with pre-diabetes at 18 years of age in women from the PMNS cohort. J Dev Orig Health Dis. https://doi.org/10.1017/S2040174422000137

35. Rose G (2001) Sick individuals and sick populations. Int J Epidemiol 30(3):427–432

36. Sattar N, Greer IA (2002) Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 325(7356):157–160

37. Jarrett RJ (1994) Gestational diabetes. Diabet Med 11(10):992–993

38. Harris MI (1988) Gestational diabetes may represent discovery of preexisting glucose intolerance. Diabetes Care 11(5):402–411

39. Simmons D, Hague WM, Teede HJ, Cheung NW, Hibbert EJ, Nolan CJ, et al (2018) Hyperglycaemia in early pregnancy: the Treatment of Booking Gestational diabetes Mellitus (TOBOGM) study. A randomised controlled trial. Med J Aust 209(9):405–406

Acknowledgements: We thank the participants, collaborators, funding agencies, and the

Diabetes Unit staff for their contribution towards this study. We would also like to thank Prof.

Clive Osmond, MRC-LEU, University of Southampton, UK for his valuable insights into the

statistical analysis.

Funding: The PMNS was funded by the Wellcome Trust, UK (038128/Z/93, 059609/Z/99,

079877/Z/06/Z, 098575/B/12/Z and 083460/Z/07/Z), MRC, UK (MR/J000094/1) and

Department of Biotechnology, GoI (BT/PR-6870/PID/20/268/2005). The PRIYA trial is

funded by the Indian Council of Medical Research (58/1/8/MRC-ICMR/2009/NCD-II) and

Medical Research Council, UK (MR/J000094/1) as part of an Indo-UK collaborative call.

The biological sample collection and analysis was funded by the DBT-CEIB grant

(BT/PR12629/MED/97/364/2016). Between these grants, the study was funded intramurally

(KEMHRC).

Authors' contributions: CY and CF conceptualized the study. SB and RW were involved in

statistical analysis. KJC, PY, RL contributed to conduct of the study. CY, CF, and RW

prepared the manuscript. DB was involved in laboratory measurements. CY is the guarantor

of this work and, as such, had full access to all the data in the study and takes responsibility

for the integrity of the data and the accuracy of the data analysis. All authors approved the

final version of the manuscript.

Declaration of interests: All the authors declare no conflicts of interest.

Table 1: Comparison of biomarkers between F1 participants with normoglycemia and hyperglycemia in pregnancy (based on quartiles of FPG and OGTT AUC at 28 weeks of gestation)

	Fasting plasma glucose			OGTT-AUC		
	Normoglycemia	Hyperglycemia	Mean Z difference (95% CI)	Normoglycemia	Hyperglycemia	Mean Z difference (95% CI)
F0 generation (Mother)	*n*=108	*n*=35		*n*=98	*n*=27	
FPG at 28wk gestation (mmol/l)	3.9	3.9	0.08 (-0.32, 0.47)	3.9	3.9	-0.02 (-0.47, 0.44)
2h glucose at 28wk gestation (mmol/l)	4.2	4.3	-0.09 (-0.58, 0.39)	4.2	4.5	0.23 (-0.22, 0.68)
F1 generation						
Birth	*n* =125	*n* =44		*n* =113	*n* =34	
Gestation (weeks)	39.1	38.7	-0.08 (-0.63, 0.46)	39	38.5	-0.2 (-0.71, 0.31)
Weight (g)	2600	2500	-0.07 (-0.43, 0.29)	2550	2475	-0.42 (-0.78, -0.05)
Length (cm)	47.4	47.7	-0.01 (-0.36, 0.34)	47.4	46.8	-0.43 (-0.82, -0.03)
2 Years	*n* =115	*n* =38		*n* =108	*n* =32	
Height (cm)	**80.7**	**81.8**	**0.41 (0.05, 0.79)**	81.2	80.1	-0.27 (-0.69, 0.16)
Weight (kg)	**9.1**	**9.7**	**0.43 (0.06, 0.79)**	9.2	9.1	-0.17 (-0.58, 0.23)
6 Years	*n* =126	*n* =44		*n* =119	*n* =38	
Height (cm)	**108.8**	**110.6**	**0.34 (0.00, 0.67)**	109.5	108.3	-0.17 (-0.56, 0.23)
Weight (kg)	**15.3**	**16.5**	**0.44 (0.10, 0.78)**	15.6	15.5	-0.04 (-0.44, 0.35)
BMI (kg/m^2)	12.9	13.4	0.32 (-0.03, 0.67)	13	12.9	0.11 (-0.29, 0.51)
Waist circumference (cm)	**49.5**	**50.4**	**0.42 (0.07, 0.76)**	50	49.8	-0.05 (-0.46, 0.36)
Fasting glucose (mmol/l)	**4.7**	**5.1**	**0.42 (0.08, 0.77)**	4.8	4.9	0.03 (-0.36, 0.41)
30-min glucose (mmol/l)	8.3	8.5	0.06 (-0.30, 0.42)	8.2	8.6	0.23 (-0.15, 0.62)
120-min glucose (mmol/l)	5.6	5.7	0.23 (-0.11, 0.58)	5.7	5.7	0.29 (-0.03, 0.61)
OGTT AUC	8.31	8.55	0.16 (-0.19, 0.51)	8.27	8.69	0.31 (-0.04, 0.66)

12 Years	*n* =125	*n* =44		*n* =118	*n* =38	
Height (cm)	139.3	142.1	0.21 (-0.12, 0.55)	139.3	140.7	0.05 (-0.31, 0.42)
Weight (kg)	**27.1**	**29.4**	**0.36 (0.10, 0.78)**	27.8	28.9	0.09 (-0.29, 0.47)
BMI (kg/m^2)	**14.2**	**14.7**	**0.42 (0.07, 0.77)**	14.4	14.3	0.01 (-0.41, 0.43)
Waist circumference (cm)	**55.5**	**56.3**	**0.35 (0.00, 0.70)**	56	55.6	0.05 (-0.36, 0.45)
Fasting glucose (mmol/l)	**4.6**	**4.8**	**0.38 (0.04, 0.71)**	4.7	4.7	0.04 (-0.30, 0.38)
	n =120	*n* =43				
Pre-pregnancy HbA1c (%), *n*=163	**5.3**	**5.5**	**0.27 (-0.07, 0.62)**	**5.3**	**5.5**	**0.11 (-0.02, 0.25)**
Pre-pregnancy HbA1c (mmol/mol), *n*=163	**34**	**37**	**0.27 (-0.07, 0.62)**	**34**	**37**	**0.11 (-0.02, 0.25)**
18 Years	*n* =120	*n* =42		*n* =113	*n* =37	
Height (cm)	156.8	158.5	0.20 (-0.15, 0.54)	157.4	156.2	-0.39 (-0.81, 0.03)
Weight (kg)	**43.9**	**47.3**	**0.50 (0.15, 0.85)**	45.6	43.9	-0.25 (-0.65, 0.15)
BMI (kg/m^2)	**17.9**	**19.1**	**0.46 (0.11, 0.81)**	18	18.3	-0.05 (-0.50, 0.39)
Underweight	**76 (63.3)**	**15 (35.7)**	***p*<0.05**	63 (55.8)	20 (54.1)	ns
Overweight/obese	**4 (3.3)**	**3 (7.1)**	***p*<0.05**	5 (4.4)	2 (5.4)	ns
Waist circumference (cm)	**66.1**	**68.8**	**0.47 (0.13, 0.82)**	67.5	66.9	-0.18 (-0.57, 0.21)
Central obesity, >=80 N(%)	4 (3.3)	3 (7.1)	ns	6 (5.3)	1 (2.7)	ns
Fasting glucose (mmol/l)	**5.1**	**5.2**	**0.49 (0.14, 0.83)**	**5.2**	**5.2**	**0.42 (0.01, 0.84)**
30-min glucose (mmol/l)	8.3	8.6	0.24 (-0.13, 0.61)	**8.3**	**8.7**	**0.47 (0.11, 0.82)**
120-min glucose (mmol/l)	6.3	6.3	-0.02 (-0.40, 0.35)	6.3	6.8	0.23 (-0.25, 0.70)
OGTT AUC	8.63	8.82	0.2 (-0.08, 0.48)	**8.62**	**9.09**	**0.38 (0.06, 0.69)**
Glucose intolerance (IFG+IGT)	23 (22.5)	11 (27.5)	ns	**16 (16.3)**	**16 (48.5)**	***p*<0.001**
Pregnancy (28 wks.)	*n* =127	*n* =44		*n* =119	*n* =39	

Height (cm)	157	158.2	0.14 (-0.21, 0.48)	157.7	156.3	-0.27 (-0.63, 0.09)
Weight (kg)	**52.5**	**58.0**	**0.60 (0.26, 0.93)**	53.5	53.7	-0.03 (-0.44, 0.37)
BMI (kg/m^2)	**21.3**	**23.3**	**0.52 (0.19, 0.86)**	21.5	22.4	0.09 (-0.32, 0.50)
Gestational weight gain (GWG, kg)	8.9	8.9	0.29 (-0.06, 0.65)	**8.5**	**10.1**	**0.42 (0.03, 0.81)**
Fasting glucose (mmol/l)	**4.3**	**4.9**	**1.63 (1.39, 1.87)**	**4.4**	**4.5**	**0.45 (0.04, 0.87)**
60-min glucose (mmol/l)	**7.5**	**7.9**	**0.37 (0.02, 0.72)**	**7.1**	**9.4**	**1.53 (1.26, 1.81)**
120-min glucose (mmol/l)	**6.2**	**6.6**	**0.42 (0.06, 0.78)**	**6.1**	**7.4**	**0.99 (0.67, 1.31)**
OGTT AUC	**7.6**	**8.26**	**0.66 (0.32, 0.10)**	**7.45**	**9.09**	**1.57 (1.38, 1.76)**
24 Years (Post-Delivery)	*n* =103	*n* =33		*n* =95	*n* =25	
Height (cm)	156.75	158	0.21 (-0.14 , 0.57)	157.5	167.4	-0.33 (-0.77, 0.12)
Weight (kg)	**49.9**	**60**	**0.70 (0.32, 1.10)**	51.0	54.0	0.03 (-0.46, 0.52)
BMI (kg/m^2)	**20.5**	**23.8**	**0.65 (0.23 , 1.07)**	20.9	21.8	0.11 (-0.40, 0.62)
Overweight/obese *n* (%)	**17 (16.5)**	**15 (45.4)**	***p*<0.01**	25 (26.6)	6 (24.0)	ns
Waist circumference (cm)	**72**	**78.7**	**0.76 (0.33 , 1.19)**	75.7	78.3	0.21 (-0.14, 0.57)
Central obesity, >=80, *n* (%)	**21 (23.3)**	**18 (60)**	***p*<0.01**	28 (32.2)	8 (33.3)	ns
Fasting glucose (mmol/l)	**4.9**	**5.3**	**0.77 (0.36 , 1.18)**	5	5.3	0.42 (-0.07, 0.92)
30-min glucose (mmol/l)	**7.9**	**8.8**	**0.66 (0.30 , 1.02)**	**8**	**8.7**	**0.56 (0.13, 0.99)**
120-min glucose (mmol/l)	5.7	6.3	0.36 (-0.06 , 0.78)	**5.7**	**6.2**	**0.42 (0.00, 0.85)**
OGTT AUC	**8.12**	**9.14**	**0.64 (0.29, 0.98)**	**8.12**	**9.04**	**0.57 (0.17, 0.97)**
Glucose intolerance (IFG+IGT)	**9 (8.7)**	**13 (38.2)**	***p*<0.001**	12 (12)	7 (26.9)	ns
F2 generation	*n* =126	*n* =43		*n* =118	*n* =38	
Male % *	51.6	58.1	-	55.1	47.4	-
Birthweight (g)	2753	2780	-	2760	2805	-
Birthweight Z-scores (INTERGROWTH)	-1.3	-0.8	0.35 (-0.07, 0.77)	-1.5	-1.4	0.11 (-0.26, 0.48)

Data is presented as median and *n* (%) as appropriate along with mean Z difference (95% CI) by *t-test*. For proportions, significance is calculated by χ^2 test, ns non-significant. The numbers (*n*) are different for different variables. The values for OGTT AUC have been divided by 100 for readability. Birthweight in g is

shown for context; the significance is shown for the sex and gestational age adjusted Z-scores (INTERGROWTH). Gestation weight gain was calculated as the difference between weight at 28wks and weight at 18-year follow-up.

Figure legends

Figure 1: The Pune Maternal Nutrition Study. F0 mothers were studied before and during pregnancy, and the F1 children were born. F1 daughters were serially followed up from birth to 24-years of age including during pregnancy and post-pregnancy, with anthropometry and cardiometabolic measurements. Their children form the F2 generation. This paper traces glucose metabolism in F1 daughters from their intrauterine life, through childhood, puberty, adulthood and into pregnancy and post-pregnancy.

Figure 2: Life course tracking of glycemia and anthropometry in F1 daughters with and without pregnancy hyperglycemia. The figure shows serial mean ± SEM at different ages. Women are classified as hyperglycemic by Q4 of FPG (A), or Q4 of OGTT AUC (B) at 28wks gestation. Those with fasting pregnancy hyperglycemia had higher FPG, BMI, and waist circumference throughout. Those with OGTT AUC pregnancy hyperglycemia had higher glycemia throughout but not BMI and waist circumference.

Figure 3: Prevalence of pregnancy hyperglycemia (28wks gestation) by quartiles of early life glycemia for fasting glucose (A) and OGTT AUC (B). The bars represent prevalence of pregnancy hyperglycemia with 95% CI. Please note OGTT AUC was not available for 12-year follow-up. There is a strong and graded association between early life glycemia and pregnancy glycemia. The forest plots show the ORs of pregnancy hyperglycemia for those in Q4 of early life glycemia

Figure 4: Prevalence of post pregnancy glucose intolerance (prediabetes, ADA criteria) by quartiles of pregnancy glycemia. The bars represent prevalence of post pregnancy glucose intolerance with 95% CI. There is a strong and graded association between pregnancy glycemia and post pregnancy glucose intolerance. The forest plots show the ORs of post-pregnancy glucose intolerance for those in Q4 of early life and pregnancy glycemia

Figure 5: Differences between the two glycemic groups shown as plots of mean difference presented as Z-scores. The figure shows difference in fasting plasma glucose, BMI, and waist circumference in participants with (a-c) normoglycemia and fasting hyperglycemia, and (d-f) normoglycemia and OGTT AUC hyperglycemia. The points represent mean values with SEM as shaded region.

Figure 1: The Pune Maternal Nutrition Study. F0 mothers were studied before and during pregnancy, and the F1 children were born. F1 daughters were serially followed up from birth to 24-years of age including during pregnancy and post-pregnancy, with anthropometry and cardiometabolic measurements. Their children form the F2 generation. This paper traces glucose metabolism in F1 daughters from their intrauterine life, through childhood, puberty, adulthood and into pregnancy and post-pregnancy.

Figure 2: Life course tracking of glycemia and anthropometry in F1 daughters with and without pregnancy hyperglycemia. The figure shows serial mean ± SEM at different ages. Women are classified as hyperglycemic by Q4 of FPG (A), or Q4 of OGTT AUC (B) at 28wks gestation. Those with fasting pregnancy hyperglycemia had higher FPG, BMI, and waist circumference throughout. Those with OGTT AUC pregnancy hyperglycemia had higher glycemia throughout but not BMI and waist circumference.

Figure 3: Prevalence of pregnancy hyperglycemia (28wks gestation) by quartiles of early life glycemia for fasting glucose (A) and OGTT AUC (B). The bars represent prevalence of pregnancy hyperglycemia with 95% CI. Please note OGTT AUC was not available for 12-year follow-up. There is a strong and graded association between early life glycemia and pregnancy glycemia. The forest plots show the ORs of pregnancy hyperglycemia for those in Q4 of early life glycemia

Figure 4: Prevalence of post pregnancy glucose intolerance (prediabetes, ADA criteria) by quartiles of pregnancy glycemia. The bars represent prevalence of post pregnancy glucose intolerance with 95% CI. There is a strong and graded association between pregnancy glycemia and post pregnancy glucose intolerance. The forest plots show the ORs of post-pregnancy glucose intolerance for those in Q4 of early life and pregnancy glycemia

Figure 5: Differences between the two glycemic groups shown as plots of mean difference presented as Z-scores. The figure shows difference in fasting plasma glucose, BMI, and waist circumference in participants with (a-c) normoglycemia and fasting hyperglycemia, and (d-f) normoglycemia and OGTT AUC hyperglycemia. The points represent mean values with SEM as shaded region.